NEW
YORK, April 30, 2024 /PRNewswire/ --
WindRose Health Investors, LLC ("WindRose"), the New
York-based healthcare private equity firm, announced that it has
completed the acquisition of SubjectWell, the patient access
marketplace that connects people with health conditions to care
options. The terms of the transaction were not disclosed.
Using a multi-channel network and precision digital outreach,
SubjectWell's marketplace of tens of millions of motivated patients
with known health conditions is growing by over 300,000 patients
per month. This marketplace, built on SubjectWell's tailored
patient recruitment technology, allows SubjectWell to support
global vaccine, chronic, rare disease and oncology clinical studies
for pharma, biotech, clinical research sites, clinical research
organizations, and other healthcare clients.
WindRose partnered with SubjectWell's executive team to acquire
the business and provide additional growth capital to advance its
next phase of expansion. With WindRose's investment, SubjectWell
will accelerate the development of both existing and new solutions
and leverage its marketplace of diverse and hard-to-access patients
to service healthcare companies needing qualified patients for
clinical trials or market-ready treatments. SubjectWell's current
management team will continue to lead the company and remain active
shareholders going forward.
"We are thrilled to be partnering with WindRose as SubjectWell
looks ahead to this next growth chapter," said Fred Martin,
CEO of SubjectWell. "WindRose selects companies whose
operational excellence is a key building block, and their team is
aligned with SubjectWell's vision. Together, we can continue to
enhance our proprietary technology, machine learning algorithms,
medical records integration and in-house medical engagement center,
all fundamental to ensuring that eligible patients – who are
desperately needed by the healthcare industry – get access to the
care they desire."
"Driving efficiency, speed, quality and access within clinical
trials has been a recurring thesis for WindRose. SubjectWell's
ability to access and match qualified patients to clinical trials
through technology and its patient marketplace helps solve a
significant pain point in the drug development lifecycle while also
increasing access to high-quality care," said CJ Burnes, Partner
with WindRose. "We are excited to partner with Fred and the
SubjectWell team as they continue to execute on their
strategy."
McDermott Will & Emery LLP
acted as legal advisor to WindRose and Silicon Legal Strategy acted
as legal advisor to SubjectWell.
About WindRose Health Investors
WindRose makes equity investments in companies that operate within
the services sectors of the healthcare industry. The firm focuses
on companies with profitable business models and a demonstrated
ability to deliver cost-effective solutions. WindRose manages
over $3.0 billion. WindRose is based in New York
City and invests in companies throughout the United States. For more information, please
email us at info@windrose.com.
About SubjectWell
SubjectWell empowers the largest direct patient access marketplace,
connecting patients with known conditions to relevant clinical
trials and market-ready treatments. With tens of millions of
patients in our marketplace, coupled with the largest patient reach
and flexible recruitment campaigns, SubjectWell supports study
designs for any therapeutic area across the globe. Visit
www.SubjectWell.com to find out more.
Contact:
Caroline Luz
Lambert
cluz@lambert.com
203-570-6462
View original content to download
multimedia:https://www.prnewswire.com/news-releases/windrose-health-investors-completes-majority-growth-investment-in-subjectwell-302130568.html
SOURCE WindRose Health Investors